Posters
Myopic laser in situ keratomileusis (LASIK) outcomes: a comparative study of three different femtosecond lasers and one mechanical microkeratome, using the same excimer laser
Poster Details
First Author: I.Rodriguez-Perez SPAIN
Co Author(s): J. Gros-Otero M. Garcia-Gonzalez M. Teus-Guezala A. Rodero-Serrano
Abstract Details
Purpose:
To compare the visual outcomes using the Intralase�Â�® (Abbott Medical Optics Inc., Santa Ana, California) versus Femto LDV�Â�® (Ziemer Ophthalmic Systems AG, Port, Switzerland) versus FS200�Â�® (Alcon Laboratories, Inc. Fort Worth, TX, USA) femto-laser platforms, versus Hansatome�Â�® zero-compression (Hansa Research and Development, Miami, Flo, USA) mechanical microkeratome, to perform myopic LASIK with the Allegretto�Â�® (WaveLight Laser Technologie AG) excimer laser.
Setting:
Clinica Novovision de MadridClinica Rementeria, Madrid.
Methods:
This is a retrospective, observational cohort study that included 550 eyes divided in four groups: 134 eyes treated with Intralase were compared to 112 refraction-matched eyes treated with Femto LDV, 206 refraction-matched eyes treated with FS200 and 98 refraction-matched eyes treated with Hansatome. Uncorrected distance visual acuity (UDVA), best corrected distance visual acuity (BCDVA) and refractive outcomes were evaluated 1 and 7 days, 1 and 3 months postoperatively.
Results:
At day one and seven post-op visits, UDVA was found significantly lower in the FS200 than in the other groups (P=0.0001), but that difference became not significant at the one and the three-month visits. Statistically significant differences were found among groups in terms of safety index (P=0.0001), residual sphere (P=0.0001) and residual cylinder (P=0.02) at three-month visit. No significant differences were found in either the BCDVA or in the efficacy index. Of the 550 eyes, 91.8% reached UDVA �â��¥ 1.0 (decimal), 4.1% lost 2 lines of BCDVA, 96.3% and 99% provided residual SE within �Â�± 0.5D and �Â�±1D, respectively.
Conclusions:
Myopia correction is safe and effective when is performed with Intralase�Â�®, Femto LDV�Â�®, FS200�Â�®, and Hansatome�Â�® in combination with Allegretto�Â�® excimer laser. In fact, we found equal visual results in all groups at the three-month follow up visit. Nevertheless, we observed a slightly slower visual recovery in FS200�Â�® group.
Financial Disclosure:
gains financially from competing product or procedure, travel has been funded, fully or partially, by a competing company, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, gains financially from product or procedure presented